Vertex Pharmaceuticals Gains EU Approval for Expanded Use of KAFTRIO in Cystic Fibrosis Treatment
Vertex Pharmaceuticals Inc has received European Commission approval for an expanded label of its cystic fibrosis treatment, KAFTRIO, allowing approximately 4,000 people in the EU to access the medication.
One minute to read
